Sterling Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sterling Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.71M	Buy	5,687 +505	+10%	+$152K	0.03%	398
2026 Q1	$1.71M	Buy	5,182 +1,625	+46%	+$553K	0.03%	365
2025 Q4	$1.41M	Buy	3,557 +730	+26%	+$323K	0.02%	527
2025 Q3	$1.29M	Sell	2,827 -9,262	-77%	-$3.77M	0.02%	555
2025 Q2	$3.94M	Sell	12,089 -1,008	-8%	-$279K	0.06%	234
2025 Q1	$3.54M	Sell	13,097 -4,990	-28%	-$1.28M	0.05%	236
2024 Q4	$4.26M	Buy	18,087 +15,507	+601%	+$4.08M	0.06%	254
2024 Q3	$710K	Buy	+2,580	New	+$672K	0.01%	704
2015 Q3	–	Sell	-9,205	Closed	-$1.1M	–	961
2015 Q2	$1.1M	Sell	9,205 -334	-4%	-$39.9K	0.01%	429
2015 Q1	$996K	Buy	+9,539	New	+$967K	0.01%	449

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's ALNY Position: Q2 2026 in Review

Sterling Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 9.7% in Q2 2026, buying an estimated $152K and bringing the position to 5,687 shares worth $1.71M. The position accounts for 0.03% of the portfolio, ranked #398.

Sterling Capital Management first reported a position in ALNY in Q1 2015 and has held it in 10 quarters since. The position peaked at $4.26M in Q4 2024. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Sterling Capital Management held 5,687 shares of Alnylam Pharmaceuticals worth $1.71M as of Q2 2026.
Sterling Capital Management bought 505 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $152K.
Alnylam Pharmaceuticals made up 0.03% of Sterling Capital Management's portfolio in Q2 2026, its #398 holding.
Sterling Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 10 quarters since.
Sterling Capital Management's Alnylam Pharmaceuticals position peaked at $4.26M in Q4 2024.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.